BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37357717)

  • 1. Piperacillin-Tazobactam Versus Anti-Pseudomonal Cephalosporins and Renal and Neurologic Outcomes in Critically Ill Adults: A Secondary Analysis of the SMART Trial.
    Qian ET; Wang L; Stollings JL; Casey JD; Rice TW; Semler MW
    J Intensive Care Med; 2023 Dec; 38(12):1127-1135. PubMed ID: 37357717
    [No Abstract]   [Full Text] [Related]  

  • 2. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.
    Qian ET; Casey JD; Wright A; Wang L; Shotwell MS; Siemann JK; Dear ML; Stollings JL; Lloyd BD; Marvi TK; Seitz KP; Nelson GE; Wright PW; Siew ED; Dennis BM; Wrenn JO; Andereck JW; Han JH; Self WH; Semler MW; Rice TW;
    JAMA; 2023 Oct; 330(16):1557-1567. PubMed ID: 37837651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol and statistical analysis plan for the Antibiotic Choice On ReNal outcomes (ACORN) randomised clinical trial.
    Qian ET; Casey JD; Wright A; Wang L; Siemann J; Dear ML; Stollings J; Lloyd BD; Seitz K; Nelson G; Wright P; Siew ED; Dennis B; Wrenn J; Andereck J; Self WH; Semler MW; Rice TW;
    BMJ Open; 2023 Mar; 13(3):e066995. PubMed ID: 36898748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the risk of acute kidney injury with the use of piperacillin/tazobactam among adult critically ill patients.
    Saad MO; Mohamed AM; Mitwally HA; Shible AA; Ait Hssain A; Abdelaty MA
    Infection; 2020 Oct; 48(5):741-747. PubMed ID: 32700095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating Renal Stress Using Pharmacokinetic Urinary Biomarker Data in Critically Ill Patients Receiving Vancomycin and/or Piperacillin-Tazobactam: A Secondary Analysis of the Multicenter Sapphire Study.
    Kane-Gill SL; Ostermann M; Shi J; Joyce EL; Kellum JA
    Drug Saf; 2019 Oct; 42(10):1149-1155. PubMed ID: 31240688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Large-Scale Multicenter Retrospective Study on Nephrotoxicity Associated With Empiric Broad-Spectrum Antibiotics in Critically Ill Patients.
    Chen AY; Deng CY; Calvachi-Prieto P; Armengol de la Hoz MÁ; Khazi-Syed A; Chen C; Scurlock C; Becker CD; Johnson AEW; Celi LA; Dagan A
    Chest; 2023 Aug; 164(2):355-368. PubMed ID: 37040818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Risk of Acute Kidney Injury in Critically Ill Children Treated With Vancomycin and Piperacillin/Tazobactam.
    Holsen MR; Meaney CJ; Hassinger AB; Fusco NM
    Pediatr Crit Care Med; 2017 Dec; 18(12):e585-e591. PubMed ID: 28906422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
    Navalkele B; Pogue JM; Karino S; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Koons J; Hussain T; Perry W; Evans R; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Kaye KS
    Clin Infect Dis; 2017 Jan; 64(2):116-123. PubMed ID: 27986669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.
    Miano TA; Hennessy S; Yang W; Dunn TG; Weisman AR; Oniyide O; Agyekum RS; Turner AP; Ittner CAG; Anderson BJ; Wilson FP; Townsend R; Reilly JP; Giannini HM; Cosgriff CV; Jones TK; Meyer NJ; Shashaty MGS
    Intensive Care Med; 2022 Sep; 48(9):1144-1155. PubMed ID: 35833959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
    Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
    JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin.
    Schreier DJ; Kashani KB; Sakhuja A; Mara KC; Tootooni MS; Personett HA; Nelson S; Rule AD; Steckelberg JM; Tande AJ; Barreto EF
    Clin Infect Dis; 2019 Apr; 68(9):1456-1462. PubMed ID: 30165426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin vs. Vancomycin/Piperacillin-Tazobactam-Associated Acute Kidney Injury in Noncritically Ill Patients at a Tertiary Care Military Treatment Facility.
    Anderson CW; Cazares KS; Lustik MB; Patel SM; Denunzio TM
    Mil Med; 2017 Sep; 182(9):e1773-e1778. PubMed ID: 28885936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin-tazobactam dosing in anuric acute kidney injury patients receiving continuous renal replacement therapy.
    Rungkitwattanakul D; Charoensareerat T; Chaichoke E; Rakamthong T; Srisang P; Pattharachayakul S; Srisawat N; Chaijamorn W
    Semin Dial; 2023; 36(6):468-476. PubMed ID: 36807546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
    Robertson AD; Li C; Hammond DA; Dickey TA
    Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
    Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS
    J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Risk of Acute Kidney Injury in Critically Ill Patients Receiving Concomitant Vancomycin With Piperacillin-Tazobactam or Cefepime.
    Molina KC; Barletta JF; Hall ST; Yazdani C; Huang V
    J Intensive Care Med; 2020 Dec; 35(12):1434-1438. PubMed ID: 30741072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.
    Blair K; Covington EW
    Ann Pharmacother; 2020 Nov; 54(11):1096-1101. PubMed ID: 32406243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin.
    Lee JD; Heintz BH; Mosher HJ; Livorsi DJ; Egge JA; Lund BC
    Clin Infect Dis; 2021 Oct; 73(7):e1579-e1586. PubMed ID: 33382398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between piperacillin/tazobactam use and acute kidney injury in critically ill patients: a retrospective multicentre cohort study.
    Tomazini BM; Besen BAMP; Taniguchi LU; Zampieri FG; Cavalcanti AB
    J Antimicrob Chemother; 2024 Mar; 79(3):552-558. PubMed ID: 38252887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.